Oral GLP-1 drugs Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
23:13
Jan 06
Zach Reitano Co-Founder and CEO, Ro CNBC
Oral GLP-1s should see broad adoption
The oral GLP-1 format should be a major commercial opportunity because it removes needle hesitancy and injection fatigue, is cheaper and less intimidating than injectables, and can attract maintenance patients who prefer a pill. It is already seeing demand from needle-phobic, injection-fatigued, and GLP-1-curious patients.
HIGH

About Oral GLP-1 drugs Investor Commentary

Across the available history and selected sources, Buzzberg tracks Oral GLP-1 drugs across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Zach Reitano.